Navigation Links
John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
Date:7/25/2012

available to patients with advanced-stage multiple myeloma and the diminished prospects for retreatment once an agent has been utilized, we believe there is a significant need in this patient population."

Two hundred and sixty-six patients received single agent carfilzomib twice weekly for 3 out of 4 weeks. The study's primary endpoint was overall response rate (ORR; ≥partial response) and secondary endpoints included clinical benefit response rate (≥minimal response), duration of response (DOR), time to progression, progression-free survival, overall survival (OS), and safety.

ORR was 23.7 percent with median DOR of 7.8 months. Median OS was 15.6 months. Adverse events (AEs) were manageable without cumulative toxicities. The researchers concluded that durable responses and an acceptable tolerability profile in this heavily-pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.

Phase 1/2 Results for Frontline Therapy for Newly Diagnosed Multiple Myeloma Patients

David H. Vesole, M.D., Ph.D., F.A.C.P., Co-Chief and Director of Research served as co-author of a study published on June 4th in Blood, which involved researchers from six leading cancer centers. The multi-center, open-label phase 1/2 study looked at carfilzomib in combination with lenalidomide and low-dose dexamethasone (CRd) as a frontline treatment for multiple myeloma.

"Triple-agent regimens with bortezomib, lenalidomide, and/or thalidomide are currently the preferred frontline strategy for newly diagnosed multiple myeloma. However, maintaining dose levels over time can be limited by the treatments' emerging toxicities," said Dr. Vesole. "This study demonstrated that the combination of carfilzomib, lenalidomide and dexamethasone is well tolerated and highly active for these patients."

The researchers enrolled 53 patients with newly-diagnosed multiple myeloma who had symptomati
'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
2. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
3. New probe provides vital assist in brain cancer surgery
4. Researchers find driver of breast cancer stem cell metastasis
5. Novel pig model may be useful for human cancer studies
6. Colonoscopy screening markedly reduces colorectal cancer incidence and death
7. A new route for tackling treatment-resistant prostate cancer
8. Antioxidants Might Help Cut Pancreatic Cancer Risk, Study Suggests
9. Young Cancer Patients Often Lack Support: Study
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. Tel Aviv University research links childhood obesity to cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... (SAN FRANCISCO, December 6, 2008) Four studies highlighting ... sickle cell disease will be presented today at the ... in San Francisco, CA. , Results from a ... improve endothelial dysfunction, a malfunction in the inner lining ...
... The use of dexamethasone early in the treatment of children ... cancer, may help reduce the risk of relapse according to ... December 6, at 2:00 p.m., during the 50th Annual Meeting ... Additional research will be featured at the press conference that ...
... 2008) A study assessing the quality of care for ... settings will be presented at a press conference on Saturday, ... of the American Society of Hematology in San Francisco, CA. ... risk in children with sickle cell disease, as well as ...
... 6, 2008) Four studies that highlight significant advances ... forms of thrombocytopenia, a group of bleeding disorders characterized ... will be presented in a press conference on Saturday, ... Meeting of the American Society of Hematology in San ...
... a call from a biotech lab in Korea. He was told ... clone of a pet dog, his beloved family mutt, Missy. Now ... healthy puppy living the good life in Mill Valley, California. “Not ... coat feels the same, and she has some of the same ...
... for Leadership on Right to Health , ... Boston (Vocus) December 5, ... community members and experts join for a landmark town meeting titled ,HIV/AIDS ... event, which commemorates World AIDS Day and the 60th anniversary of the ...
Cached Medicine News:Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 2Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 3Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 4Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 5Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 6Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 2Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 3Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 4Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 5Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 6Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 7Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 8Health News:Cloned Canine Celebrates Her 1st Birthday 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 3Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 4Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 5Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 6
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... July 21 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... extended release tablets. This product was recently approved by ... Pharma,s Abbreviated New Drug Application (ANDA). These bupropion hydrochloride ... mg, are therapeutically equivalent to GlaxoSmithKline,s Wellbutrin SR® Extended ...
... Conn. , July 21 Cara Therapeutics, ... Series D financing of $15 million .  The ... participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, ... International Corporation and MVM Life Science Partners. In conjunction ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 3
... MPD is the highly concentrated ... instruments manually or with an ultrasonic ... to remove blood and organic material ... Use MPD to clean surgical instruments ...
... need for critical patients more waveforms, ... comprehensive calculations package and cardiac output ... can transport with your patients., We ... functions which means less time ...
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
Medicine Products: